Company intelligence / Profile preview

Ario Pharma Ltd

Cambridge, England, United Kingdomlife-sciences-europe.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Ario Pharma conducted two Phase 2 clinical trials for XEN-D0501, a TRPV1 inhibitor, for chronic idiopathic cough and cough associated with COPD. The company completed multiple Phase 1 studies showing the drug was safe and well tolerated.

Therapeutic areas: Pulmonology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

XEN-D0501

Phase 2

Indications: Chronic cough

Beyond the preview

Go deeper on Ario Pharma Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ario Pharma Ltd.

Explore the full profile